Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

GHK-CuvsGonadorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/47 cited
BFDA-ApprovedHUMAN-REVIEWED7/61 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
1–2 mgSQ dosePickart 2018
HumanMechanisticPickart 2018Zink 2003
HoursHalf-life
SQ or topical · Local · Daily or 2-3×/week
Gonadorelin
GnRH Analogue · Diagnostic & Therapeutic
90 minPulsatile interval
73%Ovulation restorationTadesse 2026
2–4 minPlasma half-life
IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

01Mechanism of Action

Parameter
GHK-Cu
Gonadorelin
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
GnRH receptors on anterior pituitary gonadotropes
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026Sharma 2026
Feedback intact?
Replaces declining endogenous levels
Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH
Antibody development

02Dosage Protocols

Parameter
GHK-Cu
Gonadorelin
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
Topical concentration
0.1–2.0% in serum / cream
Frequency
Daily or 2–3× per week (SQ)
Lower / starter dose
0.5 mg / day SQ
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
RCT / Expert consensus
Duration
8–12 weeks for visible skin / hair effect
Continuous until pregnancy achieved or fertility goals met
3–6 month courses typical for ovulation induction.
Reconstitution
Bacteriostatic water; light-protected
Timing
No specific time; evening preferred for topicals
Half-life
Hours (estimated; rapid tissue uptake)
2–4 minutes (plasma)
Necessitates frequent pulsatile administration.
Diagnostic test (pituitary function)
100 mcg IV or SQ bolus
Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.
Therapeutic (hypothalamic hypogonadism)
5–20 mcg IV bolus every 90–120 minutes
Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026
Pulsatile interval
90 minutes (females) · 120 minutes (males)
Mimics physiological GnRH pulse frequency.
Route
IV preferred (therapeutic) · SQ acceptable (diagnostic)
Alternative protocols
Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

03Metabolic / Fat Loss Evidence

Parameter
GHK-Cu
Gonadorelin
Fat loss mechanism
None — gonadorelin acts exclusively on reproductive axis
Indirect metabolic effects
Restoration of sex hormones may normalize body composition in hypogonadal states
Effect mediated by downstream testosterone/estradiol, not GnRH itself.

04Side Effects & Safety

Parameter
GHK-Cu
Gonadorelin
Injection site reaction
Erythema, mild pruritus (common)
Erythema, irritation (pulsatile pump catheter site)
Topical irritation
Mild redness, transient stinging
Copper accumulation
Theoretical with very high chronic doses
Allergic reaction
Rare hypersensitivity to copper
Pregnancy / OB
Avoid topical and SQ — insufficient data
Wilson disease
Contraindicated
Headache
Common with bolus administration
Nausea / abdominal discomfort
Transient, dose-related
Ovarian hyperstimulation syndrome (OHSS)
Risk with ovulation induction protocols; monitor follicular development via ultrasound
Multiple gestation
Increased risk with fertility protocols (twins ~10–15%)
Anaphylaxis
Rare hypersensitivity reaction
Pump malfunction / infection
Mechanical failure or catheter-site infection with long-term IV pump use
Receptor desensitization
Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026
Absolute Contraindications
GHK-Cu
  • ·Wilson disease (copper-overload disorder)
  • ·Pregnancy / breastfeeding
  • ·Known copper hypersensitivity
Gonadorelin
  • ·Pregnancy (except therapeutic infertility protocols)
  • ·Hypersensitivity to gonadorelin or excipients
  • ·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
Relative Contraindications
GHK-Cu
  • ·Hemochromatosis (copper-iron crosstalk theoretical)
  • ·Concurrent copper-chelator therapy
Gonadorelin
  • ·Ovarian cysts or PCOS (monitor for OHSS)
  • ·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

05Administration Protocol

Parameter
GHK-Cu
Gonadorelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

06Stack Synergy

GHK-Cu
+ BPC-157
Moderate
View BPC-157

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu
1–2 mg SQ · daily near wound
BPC-157
250–500 mcg SQ · daily near wound
Primary benefit
Combined ECM rebuilding + angiogenesis for tissue repair
Gonadorelin
+ hCG (Human Chorionic Gonadotropin)
Multi-pathway
View hCG (Human Chorionic Gonadotropin)

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin
5–10 mcg IV every 120 min (pulsatile pump)
hCG
1500–2000 IU SQ · 2–3× per week
Duration
12–24 weeks for spermatogenesis induction
Primary benefit
Fertility restoration in hypothalamic hypogonadism with maintained testicular function